BioSpace News Archive

ESSA Pharma Inc. (“ESSA” or the “Company”) (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced its lead clinical candidate, EPI-7386, for metastatic castration-resistant prostate cancer has been selected for a poster presentation at the upcoming American Association for Cancer Research (“AACR

The loud crashes of bowling balls hitting pins filled a New York bowling alley. But the clapping and cheers that followed were not the same as those from the usual league nights.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia.

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA).

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis

Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone

After four companies successfully graduated from its acceleration program, BioSeedXL has decided to officially open its doors and offer its services to a select and hand-picked number of Biotech and Cannabis startup companies.

Company earns 100 percent on Human Rights Campaign Foundation’s 17th annual scorecard on LGBTQ Workplace Equality

Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment

AngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtrac Radiation Dose Monitoring System.